FindTrial
Sign In

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants with Active Psoriatic Arthritis

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523141-10-00
Enrollment
59
Registered
2026-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Psoriatic Arthritis

Brief summary

ACR50 response at Week 16.

Interventions

DRUGJNJ-88545223
DRUGJNJ-88545223 Placebo

Sponsors

Janssen Cilag International
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
ACR50 response at Week 16.—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 21, 2026